Edgewise Therapeutics Inc Stock

$13.06

8.86% yesterday

Nasdaq, Jun 26, 10:00 pm CET

ISIN

US28036F1057

Symbol

EWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Edgewise Therapeutics Inc Stock price

$13.06

-16.94 56.47% 5Y

Nasdaq, Closing price Thu, Jun 26 2025

-1.27 8.86%

ISIN

US28036F1057

Symbol

EWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.4b

Enterprise Value

$937.5m

Net debt

$-436.4m

Cash

$436.4m

Shares outstanding

95.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.89

Financial Health

Equity Ratio

94.33%

Return on Equity

-29.14%

ROCE

-39.25%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-167.7m | $-197.2m

EBIT

$-170.0m

Net Income

$-146.1m | $-170.2m

Free Cash Flow

$-119.4m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-37.91% | -25.98%

EBIT

-37.79%

Net Income

-38.02% | -27.23%

Free Cash Flow

-20.09%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-1.55

FCF per Share

$-1.25

Short interest

13.98%

Employees

97.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Edgewise Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Edgewise Therapeutics Inc forecast:

13x Buy

81%

3x Hold

19%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Edgewise Therapeutics Inc forecast:

Buy

81%

Hold

19%

Analyst Estimates with Stock Price Targets

Financial data from Edgewise Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	34 34	38% 38% -
- Research and Development Expense	136 136	38% 38% -
EBITDA	-168 -168	38% 38% -
- Depreciation and Amortization	2.37 2.37	30% 30% -
EBIT (Operating Income) EBIT	-170 -170	38% 38% -
Net Profit	-146 -146	38% 38% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Edgewise Therapeutics Inc Stock News

Neutral

PRNewsWire

●

about 22 hours ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings – – Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker – – Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 – – Edgewise leadership to...

Neutral

PRNewsWire

●

24 days ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

BOULDER, Colo. , June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.

Neutral

PRNewsWire

●

about one month ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

BOULDER, Colo. , May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.

More Edgewise Therapeutics Inc News

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Head office	United States
CEO	Kevin Koch
Employees	97
Founded	2017
Website	edgewisetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now